Erschienen in:
01.12.2018 | Short Communication
Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
verfasst von:
Lucien Marchand, Sophie Reffet, Stéphane Dalle, Emmanuel Disse, Julien Vouillarmet, Christine Cugnet-Anceau, Charles Thivolet
Erschienen in:
Acta Diabetologica
|
Ausgabe 3/2019
Einloggen, um Zugang zu erhalten
Excerpt
We read with interest the paper by Tassone et al., describing difficulties in achieving a good metabolic control and high glucose variability in a subject who presented nivolumab-induced fulminant diabetes (FD) [
1]. These issues were not detailed in recent reviews and the large case series of diabetes induced by immune checkpoint inhibitors. …